Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for IBT.L and 80,000+ other tickers.
See exactly how IBT.L's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IBT.L and 80,000+ other tickers.
International Biotechnology Trust plc focuses its capital allocation primarily on companies in their development and late-stage phases. A substantial portion of its assets is dedicated to publicly traded small and mid-capitalization enterprises, with a smaller allocation to larger listed firms. Pursuing a long-only investment approach, the Trust targets both quoted and unquoted biotechnology and life sciences companies, particularly those involved in drug discovery and development. Related sectors of interest encompass microbiology, broader life sciences, pharmaceutical research and…
Greenvale Energy Ltd (ASX:GRV, OTC:GVLMF) has identified 13 priority uranium targets at its Thunderball Uranium Project in the Northern Territory,...
9.58am: Stocks inch higher The FTSE 100 dropped into the red for about an hour but is now up 15 points at 10,512, with other Continental benchmarks also...
Ahead of the bell Expect a torpid start to the final trading day of the week. S&P 500 futures were flat on Friday, holding on to a week that has gone the...
International Biotechnology Trust Plc (LSE:IBT, OTC:IBITF) portfolio manager Ailsa Craig joined Proactive's Stephen Gunnion to discuss the surge in biotech...
International Biotechnology Trust Plc (LSE:IBT, OTC:IBITF) co-lead fund managers Ailsa Craig and Marek Poszepczynski tell Proactive's Stephen gunnion that...